McDermott and Wragge Advise on the Alliance Between Innate Pharma and Astrazeneca

Overview


Emmanuelle Trombe and Anthony Paronneau represented the French biotech firm Innate Pharma in signing a co-development and commercialization agreement with AstraZeneca for IPH2201, a treatment against cancer. Financial terms of the agreement include payments to Innate Pharma of up to $1.275 billion.